Clinical Scorecard: Link Between Serum Selenium Concentrations and Markers of Inflammation and Oxidative Stress in Individuals with Post-Infarction Heart Failure: An Exploratory Case-Control Investigation with In Vitro Mechanistic Insights

At a Glance

Key Highlights

• Selenium deficiency is associated with increased inflammation (IL-6, TNF-α) and oxidative stress (MDA) in post-infarction heart failure patients
• Selenium positively correlates with antioxidant capacity (SOD) and cardiac function (LVEF), supporting its cardioprotective role
• In vitro evidence demonstrates that Selenium attenuates LPS- and PA-induced pro-inflammatory and pro-fibrotic gene expression in cardiomyocytes
• Heterogeneous Selenium distribution across HF phenotypes (HFpEF, HFmrEF, HFrEF) suggests stage-dependent redox dynamics in disease progression

Guideline-Based Recommendations

Diagnosis

• HF diagnosis made according to NYHA functional classification standards

Management

• Patients on consistent standard post-infarction HF medication (e.g., ACEI/ARB, β-blockers, statins)

Monitoring & Follow-up

• Assessment of serum Selenium, inflammatory cytokines, oxidative stress markers, and LVEF

Risks

• Exclusion of patients with severe liver or kidney dysfunction, malignant tumors, infection history, autoimmune diseases, or current use of antioxidants or Selenium supplements

Patient & Prescribing Data

46 patients with heart failure secondary to prior myocardial infarction

Selenium levels were significantly lower in HF patients compared to healthy controls

Clinical Best Practices

• Consider monitoring serum Selenium levels in patients with post-infarction heart failure
• Evaluate inflammatory and oxidative stress markers as part of routine assessment in HF patients

Related Resources & Content

• Study on Selenium and Heart Failure